• Screening and tactics of severe menstrual bleeding in adolescents with defects in the hemostasis system
en To content

Screening and tactics of severe menstrual bleeding in adolescents with defects in the hemostasis system

This expert concept was developed by the Committee on Adolescent Health at the American College of Obstetricians and Gynecologists in collaboration with Oluyemisi Adeyemi-Fowode, MD and Judith Simms-Cendan, MD.
View of the Committee of Experts of the American College of Obstetricians and Gynecologists
Issue 785. – Committee on Adolescent Health
Adapted by L.V. Pakharenko
REFERENCES

1. National Institute for Health and Care Excellence. Heavy menstrual bleeding: assessment and management. London (UK), NICE. 2018. Available at: https://www.nice.org.uk/guidance/ng88. Retrieved 2019, January 7.

2. Management of acute abnormal uterine bleeding in nonpregnant reproductive-aged women. Committee Opinion 557. American College of Obstetricians and Gynecologists. Obstet Gynecol 121:891–6. 2013.

3. Venkateswaran L, Dietrich JE. 2013. Gynecologic concerns in pubertal females with blood disorders. J Pediatr Adolesc Gynecol 26:80–5.

4. Haamid F, Sass AE, Dietrich JE. 2017. Heavy menstrual bleeding in adolescents. J Pediatr Adolesc Gynecol 30:335–40.

5. Smith YR, Quint EH, Hertzberg RB. 1998. Menorrhagia in adolescents requiring hospitalization. J Pediatr Adolesc Gynecol 11:13–5.

6. Hurwitz A, Massone R, Lopez BL. 2017. Acquired bleeding disorders. Hematol Oncol Clin North Am 31:1123–45.

7. Dowlut-McElroy T, Williams KB, Carpenter SL, Strickland JL. 2015. Menstrual patterns and treatment of heavy menstrual bleeding in adolescents with bleeding disorders. J Pediatr Adolesc Gynecol 28:499–501.

8. Mikhail S, Kouides P von Willebrand disease in the pediatric and adolescent population. J Pediatr Adolesc Gynecol 23(suppl 6):S3–10. 2010.

9. Byams VR, Kouides PA, Kulkarni R, Baker JR, Brown DL, Gill JC et al. 2011. Surveillance of female patients with inherited bleeding disorders in United States haemophilia treatment centres. Haemophilia Treatment Centres Network Investigators. Haemophilia 17(suppl 1):6–13.

10. Diaz R, Dietrich JE, Mahoney D Jr, Yee DL, Srivaths LV. 2014. Hemostatic abnormalities in young females with heavy menstrual bleeding. J Pediatr Adolesc Gynecol 27:324–9.

11. Bruner AB, Joffe A, Duggan AK, Casella JF, Brandt J. 1996. Randomised study of cognitive effects of iron supplementation in non-anaemic iron-deficient adolescent girls. Lancet 348:992–6.

12. Falkingham M, Abdelhamid A, Curtis P, Fairweather-Tait S, Dye L, Hooper L. 2010. The effects of oral iron supplementation on cognition in older children and adults: a systematic review and meta-analysis. Nutr J 9:4.

13. Johnson S, Lang A, Sturm M, O’Brien SH. 2016. Iron deficiency without anemia: a common yet under-recognized diagnosis in young women with heavy menstrual bleeding. J Pediatr Adolesc Gynecol 29:628–31.

14. El-Nashar SA, Shazly SA. 2015. Pictorial blood loss assessment chart for quantification of menstrual blood loss: a systematic review. Gynecol Surg 12:157–63.

15. Sekhar DL, Murray-Kolb LE, Kunselman AR, Paul IM. 2015. Identifying factors predicting iron deficiency in United States adolescent females using the ferritin and the body iron models. Clin Nutr ESPEN 10:e118–23.

16. Powers JM, Buchanan GR. 2014. Diagnosis and management of iron deficiency anemia. Hematol Oncol Clin North Am 28:729–45, vi–vii.

17. Workowski KA, Bolan GA. 2015. Sexually transmitted diseases treatment guidelines, 2015. Centers for Disease Control and Prevention (published erratum appears in MMWR Recomm Rep. 64:924. 2015). MMWR Recomm Rep 64(RR-03):1–137.

18. Pecchioli Y, Oyewumi L, Allen LM, Kives S. 2017. The utility of routine ultrasound in the diagnosis and management of adolescents with abnormal uterine bleeding. J Pediatr Adolesc Gynecol 30:239–42.

19. Diagnosis of abnormal uterine bleeding in reproductiveaged women. Practice Bulletin 128. American College of Obstetricians and Gynecologists. Obstet Gynecol 120:197–206. 2012.

20. Tranexamic acid oral. In: Facts & Comparisons (after login). St. Louis (MO): Wolters Kluwer Health, Inc. 2019. Available at: http://fco.factsandcomparisons.com/lco/action/home. Retrieved 2019, May 20.

21. Chi C, Pollard D, Tuddenham EG, Kadir RA. 2010. Menorrhagia in adolescents with inherited bleeding disorders. J Pediatr Adolesc Gynecol 23:215–22.

22. Thorne JG, James PD, Reid RL. 2018. Heavy menstrual bleeding: is tranexamic acid a safe adjunct to combined hormonal contraception (commentary)? Contraception 98:1–3.

23. Napolitano LM, Kurek S, Luchette FA, Anderson GL, Bard MR, Bromberg W et al. 2009. Clinical practice guideline: red blood cell transfusion in adult trauma and critical care. EAST Practice Management Workgroup, American College of Critical Care Medicine (ACCM), Taskforce of the Society of Critical Care Medicine (SCCM). J Trauma 67:1439–42.

24. Parker RI. 2014. Transfusion in critically ill children: indications, risks, and challenges. Crit Care Med 42:675–90.

25. Carson JL, Stanworth SJ, Roubinian N, Fergusson DA, Triulzi D, Doree C et al. Transfusion thresholds and other strategies for guiding allogeneic red blood cell transfusion. Cochrane Database of Systematic Reviews 2016, Issue 10. Art. No.: CD002042. DOI: 10.1002/14651858.CD002042. pub4.

26. Revert M, Rozenberg P, Cottenet J, Quantin C. 2018. Intrauterine balloon tamponade for severe postpartum hemorrhage. Obstet Gynecol 131:143–9.

27. Halimeh S. 2015. Menorrhagia and postpartum haemorrhage in women with rare bleeding disorder. Thromb Res 135(suppl 1):S34–7.

28. James AH, Kouides PA, Abdul-Kadir R, Dietrich JE, Edlund M, Federici AB et al. 2011. Evaluation and management of acute menorrhagia in women with and without underlying bleeding disorders: consensus from an international expert panel. Eur J Obstet Gynecol Reprod Biol 158:124–34.

29. Hamani Y, Ben-Shachar I, Kalish Y, Porat S. 2010. Intrauterine balloon tamponade as a treatment for immune thrombocytopenic purpura-induced severe uterine bleeding. Fertil Steril 94:2769.e13–5.

30. Handa VL, Le LV. 2019. Te Linde’s atlas of gynecologic surgery. 12th ed. Philadelphia (PA), Wolters Kluwer.

31. Davies J, Kadir RA. 2017. Heavy menstrual bleeding: an update on management. Thromb Res 151(suppl 1):S70–7.

32. Kuhnz W, Heuner A, Humpel M, Seifert W, Michaelis K. 1997. In vivo conversion of norethisterone and norethisterone acetate to ethinyl etradiol in postmenopausal women. Contraception 56:379–85.

33. Levonorgestrel-releasing intrauterine system (52 mg) for idiopathic heavy menstrual bleeding: a health technology assessment. Health Quality Ontario. Ont Health Technol Assess Ser 16:1–119. 2016.

34. Gupta JK, Daniels JP, Middleton LJ, Pattison HM, Prileszky G, Roberts TE et al. 2015. A randomised controlled trial of the clinical effectiveness and cost-effectiveness of the levonorgestrel-releasing intrauterine system in primary care against standard treatment for menorrhagia: the ECLIPSE trial. ECLIPSE Collaborative Group. Health Technol Assess 19:i–xxv, 1–118.

35. Shaaban MM, Zakherah MS, El-Nashar SA, Sayed GH. 2011. Levonorgestrel-releasing intrauterine system compared to low dose combined oral contraceptive pills for idiopathic menorrhagia: a randomized clinical trial [published erratum appears in Contraception 84:112. 2011. Contraception 83:48–54.

36. Endrikat J, Shapiro H, Lukkari-Lax E, Kunz M, Schmidt W, Fortier M. 2009. A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. J Obstet Gynaecol Can 31:340–7.

37. Irvine GA, Campbell-Brown MB, Lumsden MA, Heikkila A, Walker JJ, Cameron IT. 1998. Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia. Br J Obstet Gynaecol 105:592–8.

38. Lukes AS, Reardon B, Arepally G. 2008. Use of the levonorgestrel-releasing intrauterine system in women with hemostatic disorders. Fertil Steril 90:673–7.

39. Kingman CE, Kadir RA, Lee CA, Economides DL. 2004. The use of levonorgestrel-releasing intrauterine system for treatment of menorrhagia in women with inherited bleeding disorders. BJOG 111:1425–8.

40. Schaedel ZE, Dolan G, Powell MC. 2005. The use of the levonorgestrel-releasing intrauterine system in the management of menorrhagia in women with hemostatic disorders. Am J Obstet Gynecol 193:1361–3.

41. Chi C, Huq FY, Kadir RA. 2011. Levonorgestrel-releasing intrauterine system for the management of heavy menstrual bleeding in women with inherited bleeding disorders: long-term follow-up. Contraception 83: 242–7.

42. Silva CD, Geraldes F, Silva IS. 2013. Levonorgestrel intrauterine system as a treatment option for severe menorrhagia in adolescent with type III von Willebrand disease. BMJ Case Rep 2013:bcr2013008833.

43. Stalnaker M, Esquivel P. 2015. Managing menorrhagia in a familial case of factor V deficiency. J Pediatr Adolesc Gynecol 28:e9–12.

44. Counseling adolescents about contraception. Committee Opinion 710. American College of Obstetricians and Gynecologists. Obstet Gynecol 130:e74–80. 2017.

45. Adeyemi-Fowode OA, Santos XM, Dietrich JE, Srivaths L. 2017. Levonorgestrel-releasing intrauterine device use in female adolescents with heavy menstrual bleeding and bleeding disorders: single institution review. J Pediatr Adolesc Gynecol 30:479–83.

46. McLean E, Cogswell M, Egli I, Wojdyla D, de Benoist B. 2009. Worldwide prevalence of anaemia, WHO Vitamin and Mineral Nutrition Information System, 1993–2005. Public Health Nutr 12:444–54.

47. Centers for Disease Control and Prevention, (CDC). Iron deficiency—United States, 1999–2000. MMWR Morb Mortal Wkly Rep 51:897–9. 2002.

48. Cooke AG, McCavit TL, Buchanan GR, Powers JM. 2017. Iron deficiency anemia in adolescents who present with heavy menstrual bleeding. J Pediatr Adolesc Gynecol 30: 247–50.

49. Powers JM, McCavit TL, Buchanan GR. 2015. Management of iron deficiency anemia: a survey of pediatric hematology/oncology specialists. Pediatr Blood Cancer 62: 842–6.

50. Hagan JF, Shaw JS, Duncan PM. 2017. Bright futures: guidelines for health supervision of infants, children, and adolescents, 4th ed. Elk Grove Village (IL): American Academy of Pediatrics.

51. Recommendations to prevent and control iron deficiency in the United States. Centers for Disease Control and Prevention. MMWR Recomm Rep 47(RR-3):1–29. 1998.

52. Anemia in pregnancy. ACOG Practice Bulletin 95. American College of Obstetricians and Gynecologists. Obstet Gynecol 112:201–7. 2008.

53. Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H et al. 2015. Oral iron supplements increase hepcidin and decrease iron absorption from daily or twice-daily doses in iron-depleted young women. Blood 126: 1981–9.

54. Stoffel NU, Cercamondi CI, Brittenham G, Zeder C, Geurts-Moespot AJ, Swinkels DW et al. 2017. Iron absorption from oral iron supplements given on consecutive versus alternate days and as single morning doses versus twicedaily split dosing in iron-depleted women: two open-label, randomised controlled trials. Lancet Haematol 4: e524–33.

55. Jarvis RR, Olsen ME. 2002. Type I von Willebrand’s disease presenting as recurrent corpus hemorrhagicum. Obstet Gynecol 99:887–8.

56. Radakovic B, Grgic O. 2009. Von Willebrand disease and recurrent hematoperitoneum due to the rupture of haemorrhagic ovarian cysts. Haemophilia 15: 607–9.

57. Ahuja SP, Hertweck SP. 2010. Overview of bleeding disorders in adolescent females with menorrhagia. J Pediatr Adolesc Gynecol 23(suppl 6):S15–21.

58. Kirtava A, Drews C, Lally C, Dilley A, Evatt B. 2003. Medical, reproductive and psychosocial experiences of women diagnosed with von Willebrand’s disease receiving care in haemophilia treatment centres: a case-control study. Haemophilia 9:292–7.

59. James AH. 2007. More than menorrhagia: a review of the obstetric and gynaecological manifestations of von Willebrand disease. Thromb Res 120(suppl 1):S17–20.

60. The initial reproductive health visit. Committee Opinion 598. American College of Obstetricians and Gynecologists. Obstet Gynecol 123:1143–7. 2014.

61. Menstruation in girls and adolescents: using the menstrual cycle as a vital sign. Committee Opinion 651. American College of Obstetricians and Gynecologists. Obstet Gynecol 126:e143–6. 2015.

62. National Institutes of Health. The diagnosis, evaluation, and management of von Willebrand Disease. Bethesda (MD): NIH; 2007. Available at: https://www.nhlbi.nih.gov/files/docs/ guidelines/vwd.pdf. Retrieved 2019, February 7.

63. National Heart, Lung, and Blood Institute. Available at: https://www.nhlbi.nih.gov/. Retrieved 2019, February 6.

64. National Hemophilia Foundation. Available at: www.hemophilia.org/. Retrieved 2019, January 7.

65. Hemophilia Federation of America. Available at: www.hemophiliafed.org/. Retrieved 2019, February 6.

66. Foundation for Women and Girls with Blood Disorders. Available at: http://www.fwgbd.org/. Retrieved 2019, February 6.

67. American Society of Hematology. Available at: http://www.hematology.org/. Retrieved 2019, February 6.